News

Promising Safety and Efficacy Data of Radspherin® Unveiled

Promising Safety and Efficacy Data of Radspherin® Unveiled

Promising Safety and Efficacy Data of Radspherin® Unveiled

Oncoinvent AS, a clinical stage company zeroing in on advanced alpha emitter therapy for various solid cancers, has recently shared crucial findings from their Phase 1/2a study of Radspherin®. This research focuses on patients battling colorectal cancer, showcasing its potential through a peer-reviewed publication.

Insight into the Phase 1/2a Study

The publication, which aired in a respected scientific journal, reveals that the safety and efficacy data over 18 months was derived from 23 patients enrolled in the Phase 1 segment of the RAD-18-002 study. Previously, these findings captured the attention of delegates at the 2023 Peritoneal Surface Oncology Group International Congress.

Expert Endorsements

Professor Emeritus Oyvind Bruland, MD, PhD, a senior author of this publication and one of Oncoinvent’s co-founders, expressed his satisfaction with the publication, emphasizing the implications this research holds for treating peritoneal metastases in colorectal cancer patients. He highlighted that there is a significant and pressing need for novel treatments in this area.

Challenges in Treating Metastases

According to Stein G. Larsen, MD, PhD, the principal investigator of the study and chief gastrosurgeon at Oslo University Hospital, the current treatment landscape is limited. Patients with liver and lung metastases often have access to multiple new treatment options, unlike those suffering from peritoneal metastases.

Key Findings and Implications

The published data revealed that Radspherin® demonstrated excellent tolerability following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Remarkably, at the 18-month mark, none of the patients who received the recommended dose of 7?MBq exhibited peritoneal recurrences.

Future Studies on Radspherin®

Radspherin® showed early efficacy signals that warrant additional clinical evaluation. Anticipation grows as results from an additional 24 patients treated with Radspherin® in the RAD-18-002 study are forthcoming. This may provide deeper insights into the treatment's potential impact.

Understanding the RAD-18-002 Study

Designed as a Phase 1/2a open-label trial, the RAD-18-002 study primarily aims to determine the clinical dose and evaluate Radspherin®'s safety and tolerability. It specifically targets patients with peritoneal metastases scheduled for cytoreduction and HIPEC. Recruitment for this study concluded at the end of 2023.

What is Radspherin®?

Radspherin® represents an innovative investigational radiopharmaceutical tailored for the local treatment of cancer spreading to body cavities. Formulated from billions of calcium carbonate microparticles infused with radium-224, Radspherin® utilizes the decay of radium-224 to emit alpha particles, delivering a powerful form of ionizing radiation.

Clinical Applications of Radspherin®

Radspherin® is currently being investigated in clinical studies catering to peritoneal metastases stemming from ovarian and colorectal cancer. It’s administered intraperitoneally post-surgical resection, with the goal of completely removing all detectable tumors.

The Vision of Oncoinvent AS

Oncoinvent AS strives to revolutionize cancer treatment through targeted radiopharmaceuticals. Their team comprises experienced professionals dedicated to advancing the clinical development of innovative treatments, such as Radspherin®. Their investments in internal manufacturing and supply capabilities position them well to support multi-center phase 2 clinical trials effectively.

Frequently Asked Questions

What is the purpose of the RAD-18-002 study?

The RAD-18-002 study aims to evaluate the safety, tolerability, and efficacy of Radspherin® administered to colorectal cancer patients undergoing surgery.

How many patients were involved in the study?

The initial phase involved 23 patients, with results pending from 24 additional participants.

What is Radspherin® used for?

Radspherin® is designed for locally treating cancer that has spread to body cavities, particularly focusing on colorectal and ovarian cancers.

Who are the key researchers behind this study?

Professor Oyvind Bruland and Dr. Stein G. Larsen are among the leading experts contributing to this research.

How does Radspherin® work?

Radspherin® uses radium-224's radioactive decay to emit alpha particles directly targeting cancer cells, which can enhance treatment efficacy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 149

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 66

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 36

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 49

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 191

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 11

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 161

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 18

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 70

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading

Top 5 Most Recently Viewed Articles

Settlement Reached for Just Energy Shareholders Amid Controversy

Updated Category News Views 341

Class Action Settlement Overview Recently, a significant settlement agreement was reached by representatives of former shareholders involved in a class action against Just Energy Group Inc. This move is part of the legal proceedings initiated after the company's restatement of its financial statements in 2019. Shareholders have been keenly watching the developments in...

Continue Reading
Texas Southern University Launches Impactful Lawson Endowment

Updated Category News Views 419

New Endowment Established by Texas Southern University Texas Southern University (TSU) is excited to unveil the creation of the William A. Lawson Endowment, a scholarship initiative that pays tribute to the remarkable legacy of Rev. Dr. William A. Lawson, a highly respected figure in the civil rights movement and a guiding light within the community. This endowment is...

Continue Reading
Thailand's Air Conditioner Market: Growth and Innovation Ahead

Updated Category News Views 544

Understanding the Growth Trends in Thailand's Air Conditioner Market Thailand has experienced a significant boost in its air conditioner market, projected to reach a valuation of over US$ 2,937.83 million by 2033, an increase from US$ 1,721.28 million in 2024. This growth translates to an impressive compound annual growth rate (CAGR) of 6.12% from 2025 to 2033. Several...

Continue Reading
BiomX Achieves Milestones and Reports Q2 2025 Financials

Updated Category News Views 204

BiomX Reports Second Quarter Financial Results BiomX Inc. (NYSE American: PHGE), a clinical-stage biotechnology company focused on developing innovative phage therapies, has shared its financial results and clinical updates for the second quarter of 2025, showcasing pivotal advancements that underscore its position within the industry. Positive Clinical Developments...

Continue Reading
Celebrating Community Heroes: The PuroClean Superhero Initiative

Updated Category News Views 217

PuroClean Honors Local Leaders with Superhero Day Campaign The Paramedics of Property Damage Celebrate Community Heroes Nationwide PuroClean, a renowned leader in restoration and remediation franchises, has recently concluded its captivating National Superhero Day campaign. This initiative celebrated everyday heroes across communities who have dramatically impacted lives....

Continue Reading